Mizuho Medy Co (TSE:4595) ROC (Joel Greenblatt) %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4595 Mizuho Medy Co Ltd TSE:4595
84 GF Score
Price 円1,657.00
GF Value 円1,437.57
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Mizuho Medy Co ROC (Joel Greenblatt) %?

Mizuho Medy Co TSE:4595 +0.55% 84 ROC (Joel Greenblatt) % is 0.00% as of Dec. 2025. GuruFocus rates TSE:4595 with a GF Score™ of 84/100 and a GF Value™ of 円1,437.57 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 982 Drug Manufacturers companies, Mizuho Medy Co ranks better than 59.78% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Mizuho Medy Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 0.00%.

The historical rank and industry rank for Mizuho Medy Co's ROC (Joel Greenblatt) % or its related term are showing as below:

TSE:4595' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 8.8   Med: 49.35   Max: 219.29
Current: 16.78

During the past 12 years, Mizuho Medy Co's highest ROC (Joel Greenblatt) % was 219.29%. The lowest was 8.80%. And the median was 49.35%.

TSE:4595's ROC (Joel Greenblatt) % is ranked better than
59.78% of 982 companies
in the Drug Manufacturers industry
Industry Median: 11.45 vs TSE:4595: 16.78

Mizuho Medy Co's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 21.10% per year.


Mizuho Medy Co  (TSE:4595) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Mizuho Medy Co ROC (Joel Greenblatt) % Related Terms


Mizuho Medy Co ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Mizuho Medy Co's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mizuho Medy Co ROC (Joel Greenblatt) % Chart

Mizuho Medy Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 153.16 219.29 84.83 76.53 61.65

Mizuho Medy Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 67.85 23.56 0.00 0.00 41.46

TSE:4595 vs ZTS, UTHR: ROC (Joel Greenblatt) % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Mizuho Medy Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mizuho Medy Co ROC (Joel Greenblatt) % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mizuho Medy Co's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Mizuho Medy Co's ROC (Joel Greenblatt) % falls into.


TSE:4595
84GF Score
Mizuho Medy Co Ltd TSE:4595
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mizuho Medy Co ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2585 + 3020 + 339) - (745 + 0 + 975)
=4224

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5537 + 2404 + 814) - (2130 + 0 + 530)
=6095

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Mizuho Medy Co for the quarter that ended in Dec. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0/( ( (2291 + max(4224, 0)) + (2264 + max(6095, 0)) )/ 2 )
=0/( ( 6515 + 8359 )/ 2 )
=0/7437
=0.00 %

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of 0.00% mean?
Mizuho Medy Co (TSE:4595) has a ROC (Joel Greenblatt) % of 0.00% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Mizuho Medy Co and its competitors. Over the past decade, Mizuho Medy Co's ROC (Joel Greenblatt) % has ranged from 8.80 to 219.29. According to the industry distribution chart, Mizuho Medy Co ranks #395 out of 982 companies in the Drug Manufacturers industry, placing it in the top 40.2%.
Is Mizuho Medy Co's ROC (Joel Greenblatt) % too high?
Mizuho Medy Co's current ROC (Joel Greenblatt) % is 0.00%. Over the past 10 years, this metric has ranged from a low of 8.80 to a high of 219.29. Based on the distribution chart, Mizuho Medy Co ranks #395 out of 982 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Mizuho Medy Co has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mizuho Medy Co's ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Mizuho Medy Co ranks #395 out of 982 companies for ROC (Joel Greenblatt) %. This puts Mizuho Medy Co in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 11.45. Historically, Mizuho Medy Co's own ROC (Joel Greenblatt) % has ranged from 8.80 to 219.29 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.45, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Mizuho Medy Co and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mizuho Medy Co's current ROC (Joel Greenblatt) % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mizuho Medy Co stock overvalued right now?
Based on GuruFocus' analysis, Mizuho Medy Co (TSE:4595) is currently considered Modestly Overvalued. The stock's GF Value™ is 円1,437.57, compared to a current price of 円1,657.00 — trading 15.3% above its estimated fair value. The current ROC (Joel Greenblatt) % is 0.00%. Mizuho Medy Co's overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Mizuho Medy Co (TSE:4595), the current ROC (Joel Greenblatt) % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mizuho Medy Co (TSE:4595) Overvalued in 2026?

Based on GuruFocus' analysis, Mizuho Medy Co stock appears to be overvalued. The current stock price of 円1,657.00 is trading 15.3% above its estimated GF Value™ of 円1,437.57. GuruFocus considers Mizuho Medy Co to be Modestly Overvalued.

Key valuation signals for TSE:4595:

  • ROC (Joel Greenblatt) %: 0.00%
  • GF Value™: 円1,437.57 vs. price of 円1,657.00 (15.3% above fair value)
  • GF Score™: 84/100 with 3 warning signs

No single metric tells the full story. See the TSE:4595 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mizuho Medy Co Business Description

Address 5-4 Fujinoki-machi, Saga Prefecture, Tosu, JPN, 841-0048
Mizuho Medy Co Ltd engages in research and development, manufacture, and distribution of in-vitro diagnostic products. The company provides immuno assay test products, such as influenza virus kits; Infectious diseases test kits; fecal occult blood test kits for detection of human hemoglobin and human transferrin in feces; and biochemical liquid stable reagents for professionals. It also offers HCG (midstream test), including a digital p-check test for OTC. It also offers fruit tree virus test drugs to agricultural testing places.
84GF Score

Get the complete analysis for TSE:4595

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,657.00
Price
円1,437.57
GF Value